| |
Recent News
October 18, 2011 :: |
Phase
I results for CTI 52010 in International Journal of Nanomedicine |
|
July 25, 2011 :: |
Dr. David Johnston,
CEO and Dr. Bala Subramaniam, Founder; Scientific Advisor,
will be back in India the second week of August |
|
May 20, 2011 :: |
CritiTech launches new website |
|
May 19, 2011 :: |
Dr. David Johnston,
CEO and Dr. Bala Subramaniam, Founder; Scientific Advisor,
are currently visiting India through late May |
|
May 13, 2011 :: |
Additional location
for Nanotax® Phase I trial opens at University of
Oklahoma's Peggy and Charles Stephenson Cancer Center
|
|
March 17, 2011 :: |
INDA issued for
CTI 52010 |
|
February 16, 2011 :: |
KBA
to assist CritiTech with expanding Nanotax® Trial |
news archive |
|
|
|
|
CritiTech
CritiTech specializes in optimizing the delivery
of challenging drug substances-- potent molecules, poorly
soluble compounds and biomolecules. Using our proprietary
SCF Technology and our ability to simplify formulations we
can extend the potential delivery options to oral, injection,
inhalation routes as well as to implantable devices. We thus
provide the differentiated products that truly benefit patients
in all age groups from pediatric to geriatric. We develop
products with significant commercial potential both independently
and in collaboration with strategic partners.
Our New C-FPC-411 Crystallizer
Click here for more
|
|
|
Current Clinical Trials
Nanotax®
(Ovarian Cancer)
Quick Links
eNews
Downloads
Events
Video
Portal
Case Studies
CS
#103 (Natural Product/Analgesic)
CS#104
(Natural Product/Unknown)
>case
archive
|
|
